Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
1,257. 03
+5.42
+0.433%
$
1.11T Market Cap
104.2 P/E Ratio
0.05% Div Yield
2.41M Volume
6.64 Eps
$ 1,251.61
Previous Close
Add Transaction
Day Range
1,251.25 1,274.56
Year Range
783.85 1,292.65
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why Eli Lilly (LLY) Dipped More Than Broader Market Today

Why Eli Lilly (LLY) Dipped More Than Broader Market Today

Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.

Zacks | 1 year ago
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.

Fool | 1 year ago
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders

Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders

If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.

Fool | 1 year ago
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory.

Fool | 1 year ago
Better Buy: Eli Lilly vs. Novo Nordisk.

Better Buy: Eli Lilly vs. Novo Nordisk.

It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson captured myriad headlines as each of these businesses played an integral role in the development of vaccines used to treat COVID-19.

Fool | 1 year ago
Is Eli Lilly an Undervalued Growth Stock to Buy Now?

Is Eli Lilly an Undervalued Growth Stock to Buy Now?

Eli Lilly (LLY -0.08%) is generating billions in cash flow growth due to product innovation.

Fool | 1 year ago
8 Giant Stock Champs In 2024 Predicted To Win Again In 2025

8 Giant Stock Champs In 2024 Predicted To Win Again In 2025

Missed out on giant S&P 500 winners this year like Nvidia and Eli Lilly? Don't worry: Analysts think you'll get another shot in 2025.

Investors | 1 year ago
3 Big-Name Stocks Just Announced Big-Time Dividend Increases

3 Big-Name Stocks Just Announced Big-Time Dividend Increases

These three stocks, which are at or near the top of their respective industries, just increased dividends by double-digit percentages. Below, I'll reveal how much these companies are paying out to shareholders now.

Marketbeat | 1 year ago
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Better Buy: Eli Lilly or Novo Nordisk?

Better Buy: Eli Lilly or Novo Nordisk?

In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Fool | 1 year ago
Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark

Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.

Barrons | 1 year ago
Does This News From the FDA Make Eli Lilly a Buy for 2025?

Does This News From the FDA Make Eli Lilly a Buy for 2025?

Eli Lilly (LLY 1.35%) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro.

Fool | 1 year ago
Loading...
Load More